Last reviewed · How we verify
NCT06086756
Virtual Reality Intervention for Speech Anxiety
NA trial testing Exposure intervention plus positive mood induction in Public Speaking in 48 participants. Completed in 5 December 2023.
5 December 2023
Quick facts
| Lead sponsor | Boston University Charles River Campus |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 1 November 2023 |
| Primary completion | 5 December 2023 |
| Estimated completion | 5 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Exposure intervention plus positive mood induction
- Exposure intervention plus negative mood induction
Conditions studied
- Public Speaking — all drugs for Public Speaking →
- Speech Anxiety — all drugs for Speech Anxiety →
Sponsor
Boston University Charles River Campus
Who can join
18 and older, any sex, with Public Speaking or Speech Anxiety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present study is designed to evaluate whether mood state moderates outcome to a brief VR exposure intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06086756
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Boston University Charles River Campus trials
Trials by the same sponsor.
- NCT07461584 — Memory Enhancement in Aging With Optimal Dosing · EARLY_PHASE1 · not yet recruiting
- NCT07208318 — Restructuring the Alpha-Gamma Code in Aging Vision · EARLY_PHASE1 · not yet recruiting
- NCT06182241 — Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South · NA · not yet recruiting
- NCT07158801 — Project EMPOWER-OCD · Phase 1 · not yet recruiting
- NCT05624931 — Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06086756 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston University Charles River Campus
- Last refreshed: 13 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06086756.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing